We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OriGene Technologies Announces the Acquisition of ZsBio
News

OriGene Technologies Announces the Acquisition of ZsBio

OriGene Technologies Announces the Acquisition of ZsBio
News

OriGene Technologies Announces the Acquisition of ZsBio

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OriGene Technologies Announces the Acquisition of ZsBio"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

OriGene Technologies, Inc. has announced the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio). The strategic acquisition establishes OriGene's leading position in the Chinese pathology testing market.

Headquartered in Beijing, China since 1993, ZsBio provides pathology testing products to the growing Chinese oncology diagnostic market.

ZsBio has an industry leading position in the Chinese pathology testing market because of its innovative product portfolio, expertise, strong client relationships, and has established itself as a thought leader in the Chinese pathology diagnostic field.

The Chinese pathology testing market has been experiencing double-digit growth annually and is one of the fast-growing segments of the Chinese diagnostic industry.

"With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene," commented Wei-Wu He, CEO of OriGene.

He continued, "ZsBio is already a leader in pathology products for cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories in China. In turn, OriGene brings to ZsBio innovative highly specific monoclonal antibodies and assays to complement and strengthen ZsBio's portfolio of products."

Advertisement